
Olga Zheliabina

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4978515/publications.pdf Version: 2024-02-01



0

#	Article	IF	CITATIONS
1	Comparison of the efficacy and safety of various anti-inflammatory drugs in urate-lowering therapy initiation in patients with gout (preliminary data). Sovremennaya Revmatologiya, 2021, 15, 50-56.	0.1	6
2	Urate-lowering effects of dipeptidyl peptidase-4 inhibitors. Diabetes Mellitus, 2020, 23, 349-356.	0.5	5
3	Assessment of cardiovascular risk in patients with crystal-induced arthritides and rheumatoid arthritis by the ATP III and Reynolds Risk Score. Nauchno-Prakticheskaya Revmatologiya, 2020, 58, 512-519.	0.2	5
4	Rational use of recommendations for urate-lowering therapy: clinical examples. Sovremennaya Revmatologiya, 2022, 16, 85-90.	0.1	5
5	Contributing factors of diabetes mellitus among patients with gout (results of the long-term) Tj ETQq1 1 0.78431	.4 rgBT /O	verlock 10 T
6	Impact of urate-lowering therapy on quality of life indicators in patients with gout. Sovremennaya Revmatologiya, 2021, 15, 62-68.	0.1	4
7	Risk factors for type 2 diabetes mellitus in patients with gout: results from a prospective study. Sovremennaya Revmatologiya, 2022, 16, 52-59.	0.1	4
8	Advantages of the use of metformin in patients with impaired uric acid metabolism. Terapevticheskii Arkhiv, 2021, 93, .	0.2	2
9	Colchicine for acute arthritis attacks prevention in patients with gout during urate-lowering therapy (results of a pilot study). Sovremennaya Revmatologiya, 2021, 15, 50-55.	0.1	2
10	Type 2 diabetes mellitus and gout. Nauchno-Prakticheskaya Revmatologiya, 2021, 59, 599-607.	0.2	2
11	Calcification of coronary arteries in patients with calcium pyrophosphate crystal deposition disease and knee osteoarthritis. Nauchno-Prakticheskaya Revmatologiya, 2021, 59, 411-417.	0.2	1
12	Cervical vertebrae affection in calcium pyrophosphate crystal deposition disease (description of a) Tj ETQq0 0 0 rg	$_{0.1}^{gBT/Overl}$	oçk 10 Tf 50
13	Assessment of the risk of developing type 2 diabetes mellitus in patients with gout based on the FINDRISÐ; scale. Diabetes Mellitus, 2022, 24, 521-528.	0.5	1
14	The effect of therapy on subclinical atherosclerosis of the carotid arteries in patients with calcium pyrophosphate crystal deposition disease and osteoarthritis (pilot study). Nauchno-Prakticheskaya Revmatologiya, 2021, 59, 708-714.	0.2	1
15	Effect of colchicine, methotrexate, and hydroxychloroquine therapy on cardiovascular outcomes in patients with calcium pyrophosphate crystal deposition disease. Sovremennaya Revmatologiya, 2021, 15, 76-83.	0.1	1
16	The use of an interleukin 1 inhibitor in a patient with atypical course of periodic fever. Sovremennaya Revmatologiya, 2021, 15, 81-85.	0.1	0
17	The prevalence of subclinical atherosclerosis of carotid arteries in patients with calcium pyrophosphate crystal deposition disease and osteoarthritis (pilot study). Sovremennaya Revmatologiya, 2021, 15, 33-38.	0.1	0

Association of the Q141K polymorphism of the ABCG2 gene with the effectiveness of urate-lowering therapy in patients with gout (a pilot study). Sovremennaya Revmatologiya, 2021, 15, 55-60.

#	Article	IF	CITATIONS
19	Colchicine for the treatment of COVID-19: short path from theory to practice. Meditsinskiy Sovet, 2022, , 71-79.	0.1	0